- Home
- PRME
PRME
Prime Medicine Inc.
as 06-09-2025 4:00pm EST
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 165.4M | IPO Year: | 2022 |
| Target Price: | $9.38 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $8.14 | Next Earning Date: | 05-08-2025 |
| Revenue: | $3,846,000 | Revenue Growth: | 550.76% |
| Revenue Growth (this year): | 104.12% | Revenue Growth (next year): | 196.78% |
Stock Insider Trading Activity of Prime Medicine Inc. (PRME)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Reine Allan | PRME | Chief Executive Officer | May 21 '25 | Buy | $1.18 | 125,000 | $147,150.00 | 125,000 | |
| LEE ANN L. | PRME | Chief Technical Officer | May 21 '25 | Buy | $1.13 | 100,000 | $113,000.00 | 100,000 |
Latest Prime Medicine Inc. News
PRME Breaking Stock News: Dive into PRME Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Prime Medicine to Participate in Upcoming Investor Conferences
Insider Monkey
13 days ago
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty
MT Newswires
13 days ago
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10
Zacks
18 days ago
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
MT Newswires
20 days ago
HC Wainwright Downgrades Prime Medicine to Neutral From Buy
MT Newswires
20 days ago
JPMorgan Downgrades Prime Medicine to Neutral From Overweight
MT Newswires
21 days ago
Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating
MT Newswires
21 days ago
Top Midday Decliners
Compare PRME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRME Prime Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.